CellaVision AB
Research CellaVision AB (CEVI) on Bullrun: market cap SEK 3.90B, P/E 30.2, dividend yield 1.7%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCEVI
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Market capSEK 3.90B
- P/E30.2
- Dividend yield1.7%
- Financial periodQ2 2026
- RevenueSEK 199.89M
- Net incomeSEK 32.63M
- Free cash flowSEK 11.28M
- Gross margin70.4%
Valuation Snapshot
latest market cap is SEK 3.90B; P/E is 30.2; dividend yield is 1.7%.
Peer valuation comparison
Latest P/E is 30.23x versus a Healthcare sector median of 24.46x (23.6% above).
Latest dividend yield is 1.67% versus a Healthcare sector median of 2.11% (20.9% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 758.97M | SEK 153.08M | SEK 114.26M | 68.5% | 6.42 | SEK 188.22M | SEK 25.65M | SEK 887.58M |
| FY2024 | SEK 723.22M | SEK 140.72M | SEK 186.44M | 67.3% | 5.9 | SEK 149.43M | SEK 26.85M | SEK 815.73M |
| FY2023 | SEK 677.29M | SEK 130.31M | SEK 164.67M | 68.4% | 5.46 | SEK 121.65M | SEK 64.70M | SEK 716.39M |
| FY2022 | SEK 639.34M | SEK 118.34M | SEK 113.80M | 68.6% | 4.96 | SEK 108.05M | SEK 102.50M | SEK 641.63M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 3.90B | 30.2 | 1.8% | 2.75 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.75 SEK, yield 1.7%.
| Year | Dividends/share |
|---|---|
| FY2024 | 2.25 SEK |
| FY2023 | 2.25 SEK |
| FY2022 | 2 SEK |
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CellaVision AB's market cap?
CellaVision AB's market capitalization is SEK 3.90B.
What is CellaVision AB's P/E ratio?
CellaVision AB's price-to-earnings (P/E) ratio is 30.2.
Does CellaVision AB pay a dividend?
CellaVision AB has a dividend yield of 1.7%.
What does CellaVision AB do?
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears.